As much as 70%% of malicious SWF files in the SWF-Normal dataset were collected before the first evaluation period, while less than 10%% of benign SWF files occur before the fifth evaluation period.
Two patients discontinued treatment owing to severe toxicity before the first evaluation.
Either the children did not show up, or the teeth concerned had exfoliated before the first evaluation.
Although early discontinuation of treatment before the first evaluation was caused by early progression in two patients, all responses were confirmed 1 month later.
Following enrolment, three residents died before the first evaluation and one was transferred, leaving a total of 156 participants at T1.
To evaluate the effect of the decision aid, two follow-up questionnaires will be sent to the patients, one week (t2) and eight weeks (t3) after the treatment choice, before the first evaluation of chemotherapy.
Seven patients refused participation (3 were too sick and 4 were not interested in the psychological intervention), 2 were excluded because of brain metastases and 12 died before the first evaluation.
Those patients lost to follow-up before the first evaluation time point in both the placebo (four patients) and treatment (three patients) groups had symptomatically mild OA (mean WOMAC 39.7 and 45.6, respectively).
Three patients could not be evaluated for the following reasons: one patient refused to continue chemotherapy after the first cycle, one patient died before the first evaluation probably due to rapid tumour progression, one patient was lost to the follow-up; these three patients were considered as progression disease in the final analysis.
Sixty patients (15.8%) (arm A: 14%; arm B: 9.2%; arm C: 21.6%; arm D: 15%) did not complete cycle one owing to early disease progression before the first evaluation (2.9%), intolerance (8.7%), death during therapy (1.6%), patients' wish (2.1%), and non-compliance (0.5%), respectively.
